Insigneo Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Insigneo Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-449	Closed	-$205K	–	764
2025 Q3	$205K	Buy	+449	New	+$183K	0.01%	630

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Insigneo Advisory Services's ALNY Position: Q4 2025 in Review

Insigneo Advisory Services sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 449 shares — an estimated $205K sold.

Insigneo Advisory Services first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $205K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Insigneo Advisory Services reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Insigneo Advisory Services sold 449 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $205K.
Insigneo Advisory Services first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Insigneo Advisory Services's Alnylam Pharmaceuticals position peaked at $205K in Q3 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Insigneo Advisory Services's 13F filing for Q4 2025, filed 12 Feb 2026.